Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05340621 · ClinicalTrials.gov registry record · Phase 1
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
A Phase 1 study, sponsored by OnKure.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05340621 is a Phase 1 study that has completed, run by OnKure. The registered enrollment target is 36 participants.
The verdict
NCT05340621, a Phase 1 study, has completed, sponsored by OnKure.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
Interventions
- DRUG OKI-179 + binimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2025-01-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05340621
The ClinicalTrials.gov registry entry for NCT05340621 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OnKure, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OKI-179 + binimetinib is the first listed.
NCT05340621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05340621 about?
NCT05340621 is a clinical study titled "NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)". The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
What is the current status of trial NCT05340621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-05-11. Estimated completion is 2025-01-29.
What interventions are being tested in trial NCT05340621?
The interventions under investigation include: OKI-179 + binimetinib (DRUG).
Who is sponsoring clinical trial NCT05340621?
This trial is sponsored by OnKure, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.